Evidence map›Paper›PMID 41194399›Full record

ArticleJournal of neurochemistry2025

The Serum Lipid Profile of Relapsing Multiple Sclerosis Differs Reproducibly From Healthy Controls.

Lisa Shi, Laura Ghezzi, Georgia Watt, Drishya Mainali, Dana Perantie, Chiara Fenoglio, Collin Tran, Alexander Dupuy, Freda Passam, Monokesh K Sen and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Lisa ShiCharles Perkins Centre, the University of Sydney, Sydney, New South Wales, Australia.
Laura GhezziDepartment of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy.
Georgia WattCharles Perkins Centre, the University of Sydney, Sydney, New South Wales, Australia.
Drishya MainaliCharles Perkins Centre, the University of Sydney, Sydney, New South Wales, Australia.
Dana PerantieDepartment of Neurology, Washington University, School of Medicine, St Louis, Missouri, USA.
Chiara FenoglioDepartment of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy.
Collin TranSchool of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
Alexander DupuyCharles Perkins Centre, the University of Sydney, Sydney, New South Wales, Australia.
Freda PassamCharles Perkins Centre, the University of Sydney, Sydney, New South Wales, Australia.
Monokesh K SenCharles Perkins Centre, the University of Sydney, Sydney, New South Wales, Australia.
Humphrey ChanIllawarra Shoalhaven Local Health District, New South Wales, Australia.
Samuel KwokBrain and Mind Centre, the University of Sydney, Sydney, New South Wales, Australia.
Chenyu WangSydney Neuroimaging Analysis Centre, Sydney, New South Wales, Australia.
Michael BarnettBrain and Mind Centre, the University of Sydney, Sydney, New South Wales, Australia.
Todd HardyDepartment of Neurology, Concord Hospital, Sydney, New South Wales, Australia.
Laura PiccioCharles Perkins Centre, the University of Sydney, Sydney, New South Wales, Australia.
Anthony S DonCharles Perkins Centre, the University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0003-1655-1184

Funding

Multiple Sclerosis Australia 20-0113Multiple Sclerosis Australia 21-0076Multiple Sclerosis Australia 23-0133National Health and Medical Research Council 2002660
6 · The paper itself

Abstract

Blood biomarkers that correlate with inflammatory demyelination or neurodegeneration are needed for early diagnosis and disease monitoring in multiple sclerosis (MS). This study aimed to identify serum lipids that are reproducibly altered in relapsing-remitting MS (RRMS) and correlated with indicators of disease severity. Lipids were quantified using liquid chromatography-tandem mass spectrometry in a discovery cohort of 47 RRMS, 42 other neurological disorders, and 30 healthy control serum samples, and a validation cohort of 81 RRMS, 18 progressive MS and 33 control samples. Levels were compared between groups using ANOVA adjusted for age, sex, collection site, and treatment status. Correlations of lipids with age, sex, relapse status, and expanded disability severity scale (EDSS) and multiple sclerosis severity scale (MSSS) scores were determined. Eight lysophosphatidylcholines (LPC), five lysophosphatidylethanolamines (LPE), two acylcarnitines, five diacylglycerols, three sphingomyelins (SM), one ceramide, and one hexosylceramide were significantly higher in both RRMS cohorts compared to healthy controls. Random forest models including five lipids predicted RRMS with 83% sensitivity and 77% specificity (discovery), or 89% sensitivity and 61% specificity (validation cohort). Three acylcarnitines, one brain-enriched ceramide (d18:1/18:0), and two myelin-enriched hexosylceramides were positively correlated with EDSS scores in the validation cohort, of which two were also correlated with MSSS scores. However, these associations were not observed in the discovery cohort. The neuron-enriched lipid SM(d18:1/18:0) was significantly higher during relapse in the validation and combined cohorts. In conclusion, this study identifies a set of 25 lipids that are reproducibly elevated in serum of people with RRMS. Higher serum LPCs, LPEs, diacylglycerols and acylcarnitines may reflect a peripheral lipolysis signature, while higher levels of neuron-enriched sphingolipids could reflect neurodegeneration. Future studies should investigate if these serum lipids predict brain atrophy and disability progression.

Indexed as

LipidsMultiple Sclerosis, Relapsing-RemittingAdultBiomarkersCohort StudiesFemaleHumansMaleMiddle AgedYoung AdultBiomarkersLipidsbiomarkerlipidlipidomicslysophospholipidmultiple sclerosissphingolipid

Identifiers

PMID41194399
PMCPMC12589855

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.